Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 535 clinical trials
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

The investigators therefore design this phase I/II study to investigate the safety and efficacy of lenalidomide in combination with R-DA EPOCH in patients with untreated MYC-rearranged DLBCL.

r-chop regimen
primary central nervous system lymphoma
prednisone
lenalidomide
cyclophosphamide
  • 0 views
  • 19 Feb, 2024
  • 1 location
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

myd88 gene mutation
cancer
measurable disease
serum pregnancy test
platelet transfusion
  • 0 views
  • 19 Feb, 2024
  • 2 locations
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

epirubicin
prednisone
marginal zone lymphoma
rituximab
bortezomib
  • 0 views
  • 19 Feb, 2024
  • 1 location
Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma

The purpose of this study is to determine the predictive value of a mRNA signature and liquid biopsy in patients with Diffuse Large B cell lymphoma.

lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.

lenalidomide
b-cell lymphoma
hodgkin's disease
lymphoma
rituximab
  • 0 views
  • 19 Feb, 2024
  • 1 location